Shots:
- The US FDA has approved Ohtuvayre as a maintenance therapy to treat COPD patients, with its launch anticipated in Q3’24
- The approval was based on the P-III (ENHANCE-1 & ENHANCE-2) studies analyzing Ohtuvayre monotx. or in addition with other maintenance therapies. Trials reached their 1EPs showing improved lung function; results were published in the American Journal of Respiratory and Critical Care Medicine
- Ohtuvayre is a dual PDE3 & PDE4 inhibitor which possesses both bronchodilator & non-steroidal anti-inflammatory activities. It is administered using a standard jet nebulizer into the lungs
Ref: Verona Pharma | Image: Verona Pharma | Press Release
Related News:- Botanix Pharmaceuticals’ Sofdra (Sofpironium) Receives the US FDA’s Approval to Treat Primary Axillary Hyperhidrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
